Differences in plasma MMPs and TIMPs protein expression and chemotherapy response in patients with tobacco- or wood-smoke-induced lung cancer

Respiration

Volumn 85, Issue 4, 2013, Pages 281-288

  Gonzalez Avila, Georgina ^a   Delgado, Javier ^a   Mendoza Posada, Daniel A ^a   Sommer, Bettina ^a   Ramos, Carlos ^a   Aquino Galvez, Arnoldo ^a   Camacho, Catalina ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

Gelatinase activity; Lung cancer; Matrix metalloproteinases; Never smokers; Tissue inhibitors of matrix metalloproteinases; Wood smoke

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; GELATINASE; GELATINASE A; GELATINASE B; GEMCITABINE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; NAVELBINE; PACLITAXEL; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TOBACCO SMOKE; TOXIC SUBSTANCE; UNCLASSIFIED DRUG; WOOD SMOKE; CARBOPLATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT RESPONSE; WESTERN BLOTTING; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; DENSITOMETRY; ENZYME BLOOD LEVEL; IMMUNOBLOTTING; ISOTOPE LABELING; METASTASIS POTENTIAL; MIDDLE AGED; RISK FACTOR; SMOKE; SMOKING; TOBACCO; WOOD SMOKE; ZYMOGRAPHY;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; RISK FACTORS; SMOKE; SMOKING; TISSUE INHIBITOR OF METALLOPROTEINASES; TOBACCO; TREATMENT OUTCOME; WOOD;

EID: 84876153930     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000336559     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J, Prisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Subramanian J, Govindan R: Lung cancer in never smokers: a review. J Clin Oncol 2007; 25: 561-570.
3. Rudin ChM, Avila-Tang E, Harris CC, Herman JG, Hirsh FR, Pao W, Schwartz AG, Vahakangas KH, Samet JM: Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res 2009; 15: 5646-5661.
4. Fullerton DG, Bruce N, Gordon SB: Indoor air pollution from biomass fuel smoke is a major health concern in the developing world. Trans R Soc Trop Med Hyg 2008; 102: 843-851.
5. Lissowska J, Bardin-Mikolajczak A, Fletcher T, Zaridze D, Szeszenia-Dabrowska N, Rudnai P, Fabianova E, Cassidy A, Mates D, Hoicatova I, Vitova V, Janout V, Manneje A, Brennan P, Boffeta P: Lung cancer and indoor pollution from heating and cooking with solid fuels. The IARC International Multicentre Case-Control Study in eastern/ central Europe and the UK. Am J Epidemiol 2005; 162: 326-333.
6. Delgado J, Martínez LM, Sanchez TT, Ramirez A, Iturria C, Gonzalez-Avila G: Lung cancer pathogenesis associated with wood smoke exposure. Chest 2005; 128: 124-131.
7. Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Cogliano V, WHO International Agency for Research on Cancer Monograph Working Group: Carcinogenicity of household solid fuel combustion and of high-temperature frying. Lancet Oncol 2006; 7: 977-978.
8. Torres-Duque C, Maldonado D, Perez-Padilla R, Ezzati M, Viegi G, Forum of International Respiratory Studies (FIRS) Task Force on Health: Effects of biomass exposure: biomass fuels and respiratory diseases. A review of the evidence. Proc Am Thoracic Soc 2008; 5: 577-590.
9. Scagliotti GV, Longo M, Novello S: Nonsmall cell lung cancer in never smokers. Curr Opin Oncol 2009; 21: 99-104.
10. Toh CK, Gao F, Lim WT, Leong SS, Fong KW, Yap SP, Hsu AAL, Eng Ph, Koong HN, Thirugnanam A, Tan EH: Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 2006; 24: 2245-2251.
11. Deryugina EI, Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25: 9-34.
12. Duffy MJ, McGowan PM, Gallagher WM: Cancer invasion and metastasis: changing views. J Pathol 2008; 214: 283-293.
13. Murphy G, Nagase H: Progress in matrix metalloproteinases research. Mol Aspects Med 2008; 29: 290-308.
14. Brew K, Nagase H: The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 2010; 1803.55-71.
15. Adizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavijevic D, Paccagnella A, Zatioukai P, Mazzanti P, Bisset D, Rosell R: Cisplatin- versus carboplatin- based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007; 99: 847-857.
16. Hanna N, Shepherd FA, Fossella FV, Preira JR, De Marinis F, von Pawel J, Gatzameier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr: Randomized phase III trial of pemetrexed versus docetaxel in patients with nonsmall- cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
17. Lee YJ, Kim JH, Kim SK, Ha SJ, Mok TS, Mitsudomi T, Cho BC: Lung cancer in never smokers: change of a mindset in the molecular era. Lung Cancer 2011; 72: 9-15.
18. Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK: Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 2006; 106: 2428-2436.
19. Toh CK, Wong EH, Lim WT, Leong SS, Fong KW, Wee J, Tan EH: The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer. A retrospective analysis. Chest 2004; 126: 1750-1756.
20. Mountain CF: Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-1717.
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
22. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Boeke NM, Olson BJ, Klenk DC: Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150: 76-85.
23. Sunada H, Nagai Y: A rapid microassay method for gelatinolytic activity using tritium- labeled heat-denatured polymeric collagen as a substrate and its application to the detection of enzymes involved in collagen metabolism. J Biochem 1980; 87: 1765-1772.
24. Lim WY, Seow A: Biomass fuels and lung cancer. Respirology 2012; 17: 20-31.
25. Gerber DE: EGFR inhibition in the treatment of non-small cell lung cancer. Drug Dev Res 2008; 69: 359-372.
26. Pan JH, Han JX, Wu JM, Huang HN, Yu QZ, Sheng LJ: MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-smallcell lung cancer. Respiration 2009; 78: 49-55.
27. Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 9-23.
28. Sienel W, Hellers J, Morresh-Hauf A, Lichtinghagen R, Mutschler W, Jochum M, Klein C, Passlick B, Pantel K: Prognostic impact of matrix metalloproteinase-9 in operable nonsmall cell lung cancer. Int J Cancer 2003; 103: 647-651.
29. Inesta P, Moran A, De Juan C, Gomez A, Hernando F, Garcia-Aranda C, Frias C, Diaz- Lopez A, Rodriguez-Jimenez FJ, Balibrea JL, Benito M: Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncol Rep 2007; 17: 217-223.
30. Guo CB, Wang S, Deng C, Zhang DL, Wang FL, Jin XQ: Relationship between matrix metalloproteinase 2 and lung cancer progression. Mol Diag Ther 2007; 11: 183-192.
31. Strongin AY: Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy. Biochim Biophys Acta 2010; 1803: 133-141.
32. Woessner JR, Nagase H (eds): Activation of zymogen forms of MMPs; in: Matrix Metalloproteinases and TIMPs. New York, Oxford University Press, 2000, pp 72-76.
33. Chetty C, Bhoopathi P, Joseph P, Chittivelu S, Rao JS, Lakka S: Adenovirus-mediated small interfering RNA against matrix metalloproteinase- 2 suppresses tumor growth and lung metastasis in mice. Mol Cancer Ther 2006; 5: 2289-2299.
34. Amalinei C, Caruntu ID, Giusca SE, Balan RA: Matrix metalloproteinases involvement in pathological conditions. Rom J Morphol Enbryol 2010; 51: 215-228.
35. Wojas-Krawczyk K, Krawczyk P, Mlak R, Kucharczyk T, Kowalski DM, Krzakowski M, Milanowski J: The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients. Respiration 2011; 82: 341-350.
36. Florescu M, Hasan B, Seymour L, Ding K, Shepherd FA, National Cancer Institute of Canada Clinical Trials Group: A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. J Thorac Oncol 2008; 3: 590-598.
37. Maio G: Can help for patients be too expensive? Ethical considerations and end-stage lung disease. Respiration 2011; 82: 395-399.